Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Russia's First BioPharma Public-Private Partnership Eyes Bio-Betters, Attracts $110 million

Executive Summary

Russia's bid to catch up in the global race to establish a recognized biopharma sector picked up speed with the Aug. 4 announcement of SynBio, a $110 million joint venture to develop bio-betters and innovative medicines for the Russian and international markets.

You may also be interested in...



Rusnano Teams With Domain Associates To Co-Fund Life Sciences Companies And Establish Pharma JV In Russia

Russian sovereign fund is co-investing with Domain in the VC’s portfolio life sciences companies, and the pair also will fund a manufacturing facility in Russia.

Celtic Pharma And Russia's Rusnano Set Up Pro Bono Bio, A New Firm With Philanthropic Objectives

An Anglo-Russian company, Pro Bono Bio, launches new analgesic and will price its products according to ability to pay.

Celtic Pharma And Russia's Rusnano Set Up Pro Bono Bio, A New Firm With Philanthropic Objectives

An Anglo-Russian company, Pro Bono Bio, launches new analgesic and will price its products according to ability to pay.

Related Content

Topics

UsernamePublicRestriction

Register

PS053722

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel